GT Biopharma, Inc.
GTBP
$1.14
$0.000.00%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -23.64% | -4.37% | 20.48% | 3.75% | -25.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.63% | 1.56% | 5.80% | -14.93% | -33.85% |
| Operating Income | 18.63% | -1.56% | -5.80% | 14.93% | 33.85% |
| Income Before Tax | 17.25% | -21.13% | -73.25% | -20.84% | 22.68% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 17.25% | -21.13% | -73.25% | -20.84% | 22.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 17.25% | -21.13% | -73.25% | -20.84% | 22.68% |
| EBIT | 18.63% | -1.56% | -5.80% | 14.93% | 33.85% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 47.18% | 19.08% | -24.93% | 13.54% | 42.65% |
| Normalized Basic EPS | 42.11% | 13.31% | -13.89% | 18.77% | 44.80% |
| EPS Diluted | 47.18% | 19.08% | -24.93% | 14.21% | 43.03% |
| Normalized Diluted EPS | 42.11% | 13.31% | -13.89% | 18.77% | 44.80% |
| Average Basic Shares Outstanding | 64.50% | 56.34% | 46.69% | 37.86% | 28.53% |
| Average Diluted Shares Outstanding | 64.50% | 56.34% | 46.69% | 37.86% | 28.53% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |